ATN 063: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF THE SAFETY A

ATN 063：安全性的随机、双盲、安慰剂对照试验

• 批准号: 8167361
• 负责人: LAWRENCE James D'ANGELO
• 金额: $ 1.77万
• 依托单位: CHILDREN'S RESEARCH INSTITUTE
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-01-20 至 2010-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8167361
• 关键词: Adolescent; Anti-Retroviral Agents; Computer Retrieval of Information on Scientific Projects Database; Funding; Grant; HIV Infections; Institution; Kidney; N-telopeptide; Plasma; Population; Randomized; Regimen; Research; Research Personnel; Resources; Safety; Source; Supplementation; Tenofovir; Testing; United States National Institutes of Health; Vitamin D; bone turnover; double-blind placebo controlled trial; improved; inorganic phosphate; young adult

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this study is to test the hypothesis that in a population of adolescents and young adults with HIV infection who are being treated with tenofovir as part of an antiretroviral combination regimen, vitamin D supplementation will decrease renal phosphate loss, increase plasma phosphate, decrease plasma PTH, and improve markers of bone turnover, including a decrease in plasma N-telopeptide and BAP.

该子项目是利用该技术的众多研究子项目之一 资源由 NIH/NCRR 资助的中心拨款提供。子项目和 研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金， 因此可以在其他 CRISP 条目中表示。列出的机构是 中心，不一定是研究者的机构。 本研究的目的是检验以下假设：在接受替诺福韦作为抗逆转录病毒联合治疗方案一部分的 HIV 感染青少年和年轻人中，维生素 D 补充剂将减少肾磷酸盐丢失、增加血浆磷酸盐、降低肾磷酸盐流失。血浆 PTH，并改善骨转换标志物，包括血浆 N-端肽和 BAP 的减少。